MedTrace Logo

The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure

NCT07050706 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-07-03

No results posted yet for this study

Summary

Pathological cardiac hypertrophy is characterized by abnormal cardiomyocyte metabolism, reduced myocardial contractility, and dysregulated synthesis of myocardial contractile proteins. This pathological process leads to progressive impairment of cardiac function and ultimately progresses to heart failure. Previous studies have demonstrated that PRMT5 exerts a significant inhibitory effect on heart failure, yet its clinical significance in the context of heart failure remains undefined. In this study, we hypothesized that serum PRMT5 may serve as a biomarker to predict cardiac structural parameters and functional indices. Therefore, we aim to analyse the correlation between serum PRMT5 levels and the following parameters-LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT on the first day when participants are enrolled in this study.

Conditions

  • Heart Failure, Systolic

Sponsors & Collaborators

  • The University of Hong Kong-Shenzhen Hospital

    lead OTHER

Principal Investigators

  • Assistant research fellow · The University of HongKong-Shenzhen Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07050706 on ClinicalTrials.gov